Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp15440_8k.htm |
Exhibit
99.01
|
Press
Release
|
 |
|
www.shire.com
|
New
Shire Board member
Dublin, Ireland – November 2,
2009 – The Board of Directors of Shire plc (LSE: SHP, NASDAQ: SHPGY)
announces that Mr David Stout joined the Board as a Non Executive Director with
effect from 31 October 2009.
Mr
Stout has extensive pharmaceutical experience. Most recently he was President,
Pharmaceutical Operations at GSK. In this position he had responsibility for
pharmaceutical operations in the United States, Europe, Japan and all other
International Markets. Mr Stout was also responsible for global manufacturing
and global Biologics (vaccines) at GSK. Prior to that he was President of GSK’s
US Pharmaceuticals Business and before that SmithKline Beecham’s North American
Pharmaceuticals Business. Before joining SmithKline Beecham, Mr Stout worked for
many years at Schering- Plough.
Mr
Stout holds directorships at Allos Therapeutics, Inc, Jabil Circuit, Inc. and
Airgas Inc.
Matt Emmens,
Chairman of Shire commented;
“We are delighted
to welcome David Stout to the Shire Board. He brings with him extensive
international experience in the pharmaceutical industry, which we believe will
be of great value to Shire as it continues its growth trajectory and becomes a
more global company.”
For
further information please contact:
|
Investor
Relations
|
Cléa
Rosenfeld (Rest of the World)
|
+44 1256 894
160
|
|
Eric Rojas
(North America)
|
+1 617 551
9715
|
|
|
Media
|
Jessica Mann
(Rest of the World)
|
+44 1256 894
280
|
|
Matthew
Cabrey (North America, Specialty Pharma)
|
+1 484 595
8248
|
|
|
Jessica
Cotrone (North America, HGT)
|
+1 617 613
4640
|
Notes
to editors
SHIRE
PLC
Shire’s strategic
goal is to become the leading specialty biopharmaceutical company that focuses
on meeting the needs of the specialist physician. Shire focuses its
business on attention deficit hyperactivity disorder (ADHD), human genetic
therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in
other therapeutic areas to the extent they arise through
acquisitions. Shire’s in-licensing, merger and acquisition efforts
are focused on products in specialist markets with strong intellectual property
protection and global rights. Shire believes that a carefully
selected and balanced portfolio of products with strategically aligned and
relatively small-scale sales forces will deliver strong results.
For further
information on Shire, please visit the Company’s website: www.shire.com.